CADTH Makes Positive Recommendation for Public Reimbursement of DupixentTM

ESC is delighted to share that the Canadian Agency for Drugs and Technologies in Health (CADTH) has provided a positive recommendation for public drug plan reimbursement of Dupixent, the first biologic therapy for atopic dermatitis (AD), the most common form of eczema.  Dupixent’s indication was previously for patients aged 18 and older, and was recently expanded to include patients 12 years and older, for the treatment of moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies.

This expanded indication and positive recommendation from CADTH are steps forward for the many Canadians suffering with unmanaged atopic dermatitis. For adolescents suffering with unmanageable AD the symptoms can significantly impair their quality of life, and compound the stressors already associated with the teen years.

ESC is pleased and hopeful that the provinces will take this recommendation and reimburse this medication for patients in need.  Public drug plan access to Dupixent would fill a significant gap for Canadians with uncontrolled AD.

The next step in this process will be for Dupixent’s manufacturer to finalize an agreement at the pan-Canadian Pharmaceutical Alliance – an organization made up of representatives of all provincial Health Ministries that negotiates with drug manufacturers on the conditions and pricing for public listings. We will continue to provide updates on the status of Dupixent negotiations and its subsequent coverage across Canada.

For more information on the CADTH recommendation, or to read ESC’s patient input submission, visit: https://www.cadth.ca/dupilumab-0.